According to recent reports, Anchor Capital Advisors LLC has sold 15,484 shares of Charles River Laboratories International, Inc. (CRL). Moreover, there's insider activity as Joseph Laplume sold 4,400 shares of CRL, while James Foster, Chairman of CRL, bought 2.5% more shares. Various investment firms are altering their stakes in CRL, including Bell Global Equities and Versor Investments LP, which respectively sold its investment and established a new one because of potential ongoing risks to its revenues.
Given CRL's recent underperformance, questions continue to persist whether Wall Street is bullish or bearish on the stock. Latest price target adjustments by TD Cowen and JPMorgan Chase & Co. have tried answering the persisting question.
CRL has announced several strategic collaborations recently, such as with Singapore General Hospital and Deciphex for advanced digital pathology solutions, aiming to diversify its operations amidst political headwinds.
Despite a full year 2024 earnings miss, CRL remains upbeat about the future, providing optimistic FY25 earnings guidance. Noticeably, the introduction of the global Biotech incubator program and the expansion of CRL's Apollo™ ecosystem focus on turning research operations revolutionary.
Charles River Laboratories International CRL News Analytics from Mon, 03 Jun 2024 07:00:00 GMT to Sat, 01 Mar 2025 12:03:25 GMT - Rating -1 - Innovation 3 - Information 9 - Rumor -7
